# NCT05740943 (NCT05740943)

> Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05740943
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Guangdong Provincial People's Hospital
- Conditions: Stage III NSCLC; Surgery
- Interventions: Lorlatinib
- Enrollment: 48
- Primary outcome: Pathological Complete Response (pCR)

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05740943